Karyopharm Therapeutics (KPTI) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- Reddit to join S&P 500 index on Aug. 18, shares leap
Karyopharm Reports Second Quarter 2017 Financial Results and Highlights Recent Progress
August 8, 2017 7:01 AM EDTPivotal Phase 3 BOSTON Study Underway
Updated Phase 1b/2 STOMP Data Expected by Year End 2017; Top-line Phase 2b STORM Data Expected by April 2018
Phase 2 SEAL Hazard Ratio Expected in September/October 2017, Along with Other Pipeline Program Updates During the Second Half of 2017
Conference Call Scheduled for Today at 8:30 a.m. ET
NEWTON, Mass., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today reported financial results for the second quarter 2017 and commented on recent accomplishments and... More
